CorMedix
CRMD
65 hedge funds and large institutions have $44.7M invested in CorMedix in 2023 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 19 reducing their positions, and 9 closing their positions.
0% more funds holding
Funds holding: 65 → 65 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
1.46% less ownership
Funds ownership: 27.53% → 26.06% (-1.5%)
5% less capital invested
Capital invested by funds: $47M → $44.7M (-$2.37M)
11% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 19
31% less call options, than puts
Call options by funds: $833K | Put options by funds: $1.21M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$575K |
| 2 |
Renaissance Technologies
New York
|
+$442K |
| 3 |
Jane Street
New York
|
+$392K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$392K |
| 5 |
WCP
Wick Capital Partners
Wayne,
Pennsylvania
|
+$224K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cresset Asset Management
Chicago,
Illinois
|
-$1.31M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$1.22M |
| 3 |
Millennium Management
New York
|
-$1.1M |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$229K |
| 5 |
PIC
Portland Investment Counsel
Burlington,
Ontario, Canada
|
-$165K |
CRMD Hedge Fund Activity: Q1 2023 in Review
65 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q1 2023, worth a combined $44.7M — down 5% from $47M a quarter earlier.
Fund positioning in CRMD was balanced in Q1 2023: 9 funds opened new positions, 9 closed out, 17 added to existing stakes and 19 trimmed.
The largest buyer was Vanguard Group, adding an estimated $575K. The largest seller was Cresset Asset Management, exiting entirely with an estimated $1.31M sold.
- 65 institutional investors held CorMedix (CRMD) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $44.7M of CorMedix stock for Q1 2023, down 5% quarter-over-quarter.
- 9 funds opened new CorMedix positions in Q1 2023 and 9 closed out, a net change of 0 holders.
- The largest CorMedix buyer in Q1 2023 was Vanguard Group, an estimated $575K added.
- The largest CorMedix seller in Q1 2023 was Cresset Asset Management, an estimated $1.31M sold.
Based on aggregated 13F filings for Q1 2023.